Evidence map›Paper›PMID 28504409›Full record

ArticleAdvanced healthcare materials2017

Multifunctional Liposomes for Image-Guided Intratumoral Chemo-Phototherapy.

Dyego Miranda, Kevin Carter, Dandan Luo, Shuai Shao, Jumin Geng, Changning Li, Upendra Chitgupi, Steven G Turowski, Nasi Li, G Ekin Atilla-Gokcumen and 2 more

Open access · greenAbstract read
In one paragraph

Article in Advanced healthcare materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Labeling of Erythrocytes by Porphyrin-Phospholipid.Advanced nanobiomed research · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dyego MirandaDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Kevin CarterDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Dandan LuoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Shuai ShaoDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Jumin GengDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Changning LiDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Upendra ChitgupiDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Steven G TurowskiDepartment of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Nasi LiDepartment of Chemistry, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
G Ekin Atilla-GokcumenDepartment of Chemistry, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Joseph A SpernyakDepartment of Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.ORCID http://orcid.org/0000-0002-9052-884X
University at Buffalo, State University of New York · USRoswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Light-Triggered Drug Release in Primed Pancreatic TumorsR01EB017270 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2021
$3.5M
Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR LightDP5OD017898 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2017
$1.9M
NCI NIH HHS P30 CA016056NIBIB NIH HHS R01 EB017270NIH HHS DP5 OD017898
6 · The paper itself

Abstract

Intratumoral (IT) drug injections reduce systemic toxicity, but delivered volumes and distribution can be inconsistent. To improve IT delivery paradigms, porphyrin-phospholipid (PoP) liposomes are passively loaded with three hydrophilic cargos: sulforhodamine B, a fluorophore; gadolinium-gadopentetic acid, a magnetic resonance (MR) agent; and oxaliplatin, a colorectal cancer chemotherapeutic. Liposome composition is optimized so that cargo is retained in serum and storage, but is released in less than 1 min with exposure to near infrared light. Light-triggered release occurs with PoP-induced photooxidation of unsaturated lipids and all cargos release concurrently. In subcutaneous murine colorectal tumors, drainage of released cargo is delayed when laser treatment occurs 24 h after IT injection, at doses orders of magnitude lower than systemic ones. Delayed light-triggering results in substantial tumor shrinkage relative to controls a week following treatment, although regrowth occurs subsequently. MR imaging reveals that over this time frame, pools of liposomes within the tumor migrate to adjacent regions, possibly leading to altered spatial distribution during triggered drug release. Although further characterization of cargo loading and release is required, this proof-of-principle study suggests that multimodal theranostic IT delivery approaches hold potential to both guide injections and interpret outcomes, in particular when combined with chemo-phototherapy.

Indexed as

Antineoplastic AgentsContrast MediaFluorescent DyesLiposomesAnimalsCell Line, TumorCell SurvivalFemaleMagnetic Resonance ImagingMiceMice, Inbred BALB COrganoplatinum CompoundsOxaliplatinPhospholipidsPhotochemotherapyPorphyrinsAntineoplastic AgentsContrast MediaFluorescent DyesLiposomesOrganoplatinum CompoundsOxaliplatinPhospholipidsPorphyrinschemo-phototherapyintratumorallight-triggeredliposomesoxaliplatin

Identifiers

PMID28504409
PMCPMC5568974
OpenAlexW2615084686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.